StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$74.18−3.48 (-4.48%)

Close on Nov 17, 2026Market cap $1.09BP/E –Yield –

Inhibrx Biosciences cash

Cash and short-term investments held at the end of each period.

Inhibrx Biosciences's cash was $199.47M at Sep 30, 2026. For fiscal 2025 it was $124.22M, down 18.6% from the year before. The highest annual figure on record is $277.92M in fiscal 2023.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$124.22M-18.6%
FY2024Dec 31, 2024$152.60M-45.1%
FY2023Dec 31, 2023$277.92M+1.5%
FY2022Dec 31, 2022$273.87M+108.6%
FY2021Dec 31, 2021$131.30M+2.0%
FY2020Dec 31, 2020$128.66M+1014.9%
FY2019Dec 31, 2019$11.54M+448.7%
FY2018Dec 31, 2018$2.10M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$199.47M+30.3%
Q2 FY2026Jun 30, 2026$133.34M-28.5%
Q1 FY2026Mar 31, 2026$161.66M-25.3%
Q4 FY2025Dec 31, 2025$124.22M-18.6%
Q3 FY2025Sep 30, 2025$153.09M-22.0%
Q2 FY2025Jun 30, 2025$186.57M-17.8%
Q1 FY2025Mar 31, 2025$216.52M-14.2%
Q4 FY2024Dec 31, 2024$152.60M-45.1%
Q3 FY2024Sep 30, 2024$196.33M-41.8%
Q2 FY2024Jun 30, 2024$226.86M+17.9%
Q1 FY2024Mar 31, 2024$252.48M+7.8%
Q4 FY2023Dec 31, 2023$277.92M+1.5%
Q3 FY2023Sep 30, 2023$337.33M+130.9%
Q2 FY2023Jun 30, 2023$192.49M+9.1%
Q1 FY2023Mar 31, 2023$234.25M+63.3%
Q4 FY2022Dec 31, 2022$273.87M+108.6%
Q3 FY2022Sep 30, 2022$146.07M+29.6%
Q2 FY2022Jun 30, 2022$176.39M+40.3%
Q1 FY2022Mar 31, 2022$143.47M+32.9%
Q4 FY2021Dec 31, 2021$131.30M+2.0%
Q3 FY2021Sep 30, 2021$112.70M-11.7%
Q2 FY2021Jun 30, 2021$125.73M+2132.4%
Q1 FY2021Mar 31, 2021$107.99M+25131.3%
Q4 FY2020Dec 31, 2020$128.66M+1014.9%
Q3 FY2020Sep 30, 2020$127.67M+426.3%
Q2 FY2020Jun 30, 2020$5.63M+167.8%
Q1 FY2020Mar 31, 2020$428.00K–
Q4 FY2019Dec 31, 2019$11.54M–
Q3 FY2019Sep 30, 2019$24.26M–
Q4 FY2018Dec 31, 2018$2.10M–

More Inhibrx Biosciences figures

See a number that looks wrong?